Insulet Q4 Revenue Up 31.2% to $783.8M; $350M Buyback Boost
Insulet reported Q4 revenue of $783.8 million, up 31.2% year-over-year and exceeding the $768.6 million consensus, while EPS of $1.44 narrowly missed estimates of $1.46. Omnipod revenue climbed 33.5% to $781.8 million, and the board authorized a $350 million increase in share repurchase plan.
1. Strong Q4 Financial Results
Insulet delivered fourth-quarter revenue of $783.8 million, surpassing the $768.6 million analyst consensus and marking a 31.2% year-over-year increase. Reported EPS of $1.44 narrowly trailed the $1.46 estimate, reflecting modest margin pressure despite robust top-line growth.
2. Omnipod Segment Growth
The Omnipod product line generated $781.8 million in Q4 revenue, up 33.5% year-over-year, driven by U.S. sales of $567.8 million (28% growth) and international revenue of $214 million (50.7% growth). Insulet also reached over 600,000 estimated active Omnipod users globally.
3. 2026 Guidance
For first-quarter 2026, Insulet forecasts constant-currency revenue growth of 25%–27% with Omnipod revenue up 28%–30%. Full-year 2026 guidance calls for 20%–22% constant-currency revenue growth, approximately 100 basis points of adjusted operating margin expansion, and over 25% adjusted EPS growth.
4. Share Repurchase Authorization
Insulet’s board approved a $350 million increase to its share repurchase authorization, with plans to deploy roughly $300 million toward repurchases during the first quarter of 2026.